Zacks Research Analysts Reduce Earnings Estimates for Eli Lilly and Company (NYSE:LLY)

Eli Lilly and Company (NYSE:LLY) – Research analysts at Zacks Research decreased their Q1 2025 EPS estimates for Eli Lilly and Company in a research report issued on Wednesday, April 17th. Zacks Research analyst K. Shah now expects that the company will earn $4.77 per share for the quarter, down from their previous estimate of $4.80. The consensus estimate for Eli Lilly and Company’s current full-year earnings is $12.52 per share. Zacks Research also issued estimates for Eli Lilly and Company’s Q2 2025 earnings at $4.07 EPS, Q3 2025 earnings at $4.46 EPS, Q4 2025 earnings at $4.50 EPS and FY2025 earnings at $17.80 EPS.

Other equities analysts have also issued reports about the stock. JPMorgan Chase & Co. upped their target price on shares of Eli Lilly and Company from $775.00 to $850.00 and gave the stock an “overweight” rating in a research report on Friday, March 15th. Barclays increased their price objective on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a report on Wednesday, February 7th. Cantor Fitzgerald restated an “overweight” rating and issued a $815.00 price objective on shares of Eli Lilly and Company in a report on Monday, April 15th. The Goldman Sachs Group increased their price objective on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a report on Thursday, April 11th. Finally, Citigroup increased their price objective on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a report on Tuesday, April 2nd. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $728.05.

Eli Lilly and Company Price Performance

Shares of LLY stock opened at $726.31 on Thursday. Eli Lilly and Company has a 1 year low of $369.76 and a 1 year high of $800.78. The firm’s 50 day moving average is $763.96 and its 200-day moving average is $659.59. The firm has a market capitalization of $690.11 billion, a price-to-earnings ratio of 125.23, a PEG ratio of 1.64 and a beta of 0.34. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The company had revenue of $9.35 billion for the quarter, compared to analyst estimates of $8.95 billion. During the same period in the prior year, the business earned $2.09 earnings per share. Eli Lilly and Company’s quarterly revenue was up 28.1% on a year-over-year basis.

Insider Transactions at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 54,032 shares of the stock in a transaction on Monday, January 29th. The shares were sold at an average price of $645.07, for a total transaction of $34,854,422.24. Following the completion of the sale, the insider now owns 99,488,598 shares of the company’s stock, valued at $64,177,109,911.86. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.13% of the stock is owned by insiders.

Institutional Investors Weigh In On Eli Lilly and Company

Several large investors have recently made changes to their positions in the stock. Maryland State Retirement & Pension System increased its position in shares of Eli Lilly and Company by 0.6% during the first quarter. Maryland State Retirement & Pension System now owns 66,151 shares of the company’s stock worth $49,308,000 after acquiring an additional 363 shares in the last quarter. Cohen Investment Advisors LLC grew its position in Eli Lilly and Company by 9.9% in the first quarter. Cohen Investment Advisors LLC now owns 11,483 shares of the company’s stock valued at $8,933,000 after purchasing an additional 1,033 shares in the last quarter. Kesler Norman & Wride LLC grew its position in Eli Lilly and Company by 313.4% in the first quarter. Kesler Norman & Wride LLC now owns 2,985 shares of the company’s stock valued at $2,322,000 after purchasing an additional 2,263 shares in the last quarter. Mezzasalma Advisors LLC grew its position in Eli Lilly and Company by 110.3% in the first quarter. Mezzasalma Advisors LLC now owns 6,243 shares of the company’s stock valued at $4,857,000 after purchasing an additional 3,275 shares in the last quarter. Finally, FORVIS Wealth Advisors LLC grew its position in Eli Lilly and Company by 38.6% in the first quarter. FORVIS Wealth Advisors LLC now owns 61,819 shares of the company’s stock valued at $48,093,000 after purchasing an additional 17,222 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.